Current status of implementation of self-administration training in various regions of Europe, Canada and the USA in the management of hereditary angioedema

International Archives of Allergy and Immunology

Volumn 161, Issue , 2013, Pages 10-16

  Caballero, T ^a   Sala Cunill, A ^b   Cancian, M ^c   Craig, T J ^e   Neri, S ^d   Keith, P K ^f   Boccon Gibod, I ^g   Bethune, C ^h   Bork, K ⁱ  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h DERRIFORD HOSPITAL   (United Kingdom)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Benefits; Current status; Hereditary angioedema; Quality of life; Self administration

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ICATIBANT;

ANGIONEUROTIC EDEMA; ARTICLE; CANADA; COST CONTROL; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG SELF ADMINISTRATION; FOLLOW UP; GERMANY; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN; ITALY; LONG TERM CARE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; UNITED STATES;

EID: 84878003349     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000351233     Document Type: Article

References (33)

1. Dagen C, Craig TJ: Treatment of hereditary angioedema: items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol 2010; 6: 11.
2. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López-Trascasa M: Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94: 498-503.
3. Zuraw BL: Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
4. Bygum A: Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009; 161: 1153-1158.
5. Lunn ML, Santos CB, Craig TJ: Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol 2010; 104: 211-214.
6. Cicardi M, Johnston DT: Hereditary and acquired complement component 1 esterase inhibitor deficiency: a review for the hematologist. Acta Haematol 2012; 127: 208-220.
7. Prematta MJ, Kemp JG, Gibbs JG, Mende C, Rhoads C, Craig TJ: Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc 2009; 30: 506-511.
8. Prematta MJ, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, Craig TJ: Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther 2012; 29: 913-922.
9. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, Stark D, Sur S, Tsai E, Warrington R, Waserman S, Ameratunga R, Bernstein J, Björkander J, Brosz K, Brosz J, Bygum A, Caballero T, Frank M, Fust G, Harmat G, Kanani A, Kreuz W, Levi M, Li H, Martinez-Saguer I, Moldovan D, Nagy I, Nielsen EW, Nordenfelt P, Reshef A, Rusicke E, Smith-Foltz S, Späth P, Varga L, Xiang ZY: 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
10. HAEi: Sanquin Blood Supply Foundation has been granted marketing authorization for their plasma-derived C1-inhibitor product Cetor in Belgium, Luxembourg, France and Finland. 2010. http://www.haei.org/node/1181 (accessed 03 January 2013).
11. CSL Behring: CSL Behring receives European Health Authorities' approval for self-administration of Berinert ®. 2011. http://www. cslbehring.com/news-room/europeanhealth-authorities-approve-self-adminstration-of-berinert.htm (accessed 21 November 2012).
12. CSL Behring: CSL Behring receives FDA approval of expanded label on Berinert ® for selfadministration and treatment of acute laryngeal attacks of hereditary angioedema. 2012. http://www.cslbehring-us.com/news-room/HAE-Berinert-Self-Administration-and-Laryngeal-Attacks (accessed 21 November 2012).
13. ViroPharma Inc.: ViroPharma's Cinryze ® (C1 inhibitor [human]) granted European marketing authorization for hereditary angioedema (HAE). 2011. http://ir.viropharma. com/releasedetail.cfm?ReleaseID=585060 (accessed 21 November 2012).
14. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris C. H, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick C. H, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
15. Pharmiweb.com: European Commission approves self-administration label for Firazyr ® (icatibant) for the symptomatic treatment of acute hereditary angioedema attacks. 2011. http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW-ID=37878#axzz2C m0UVl3D (accessed 21 November 2012).
16. Riedl M, Campion M, Horn PT, Pullman WE: Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 2010; 105: 430-436.
17. Caballero T, López-Serrano C: Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 2006; 117: 476-477.
18. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE: Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-827.
19. Bork K: Current management options for hereditary angioedema. Curr Allergy Asthma Rep 2012; 12: 273-280.
20. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, Bork K, Bouillet L, Boysen H, Bygum A, Caballero T, Cicardi M, Dempster J, Gompels M, Gooi J, Grigoriadou S, Huffer U, Kreuz W, Levi MM, Long J, Martinez-Saguer I, Raguet M, Reshef A, Bowen T, Zuraw B: HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
21. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B, HAWK: Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
22. Food and Drug Administration: FDA approves Firazyr to treat acute attacks of hereditary angioedema. 2011. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm269616.htm (accessed 20 September 2012).
23. CSL Behring: CSL Behring received MHRA approval for self-administration of Berinert ® (C1 esterase inhibitor, human). 2012. http://www.cslbehring.co.uk/s1/cs/beuk/1161072713064/news/1255928888774/prdetail. htm (accessed 21 November 2012).
24. CSL Behring: CSL Behring receives European Health Authorities' approval of Berinert® for short-term prophylaxis in adults and children. 2013. http://www.cslbehring.com/s1/c s/e n c o/1 1 5 1 5 1 7 2 6 3 3 0 2/n e w s/1255931201677/prdetail.htm (accessed 17 April 2013).
25. ViroPharma Inc.: ViroPharma receives Complete Response letter for CinryzeTM supplemental Biologics License Application for acute treatment of hereditary angioedema. 2009. http://ir.viropharma.com/releasedetail. cfm?ReleaseID=543136 (accessed 21 November 2012).
26. Levi M, Choi G, Picavet C, Hack CE: Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-908.
27. Bork K, Staubach P, Bernstein JA, Feuersenger H, Machnig T, Craig TJ: Efficacy of C1-inhibitor concentrate (Berinert ® ) for the treatment of cutaneous attacks of acute hereditary angioedema compared to historical untreated controls. J Allergy Clin Immunol 2013; 131:AB31.
28. Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G, Kaplan A, Longhurst H, Zanichelli A, IOS Investigators: Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS ONE 2013; 8:e53773.
29. Costantino G, Casazza G, Bossi I, Duca P, Cicardi M: Long-term prophylaxis in hereditary angio-oedema: a systematic review. BMJ Open 2012; 2:e000524.
30. Cicardi M, Craig T, Martinez-Saguer I, Hébert J, Longhurst HJ: Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013; 161(suppl 1):3-9.
31. Symons C, Rossi O, Magerl M, Andritschke K: Practical approac to self-administration of intravenous C1-INH concentrate: a nursing perspective. Int Arch Allergy Immunol 2013; 161(suppl 1):17-20.
32. Boysen HB, Bouillet L, Aygören-Pürsün E: Challenges of C1-inhibitor concentrate selfadministration. Int Arch Allergy Immunol 2013; 161(suppl 1):21-25.
33. Boccon-Gibod I, Bouillet L: Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012; 168: 303-307.